USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer
| Autor: | Kelly K. Hunt, Jennifer K. Litton, Gabriel N. Hortobagyi, Banu Arun, Diane Liu, Soley Bayraktar, Lajos Pusztai, Fraser Symmans, Angelica M. Gutierrez Barrera, Vicente Valero, Yun Wu |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Breast Neoplasms Disease Logistic regression Systemic therapy Article Breast cancer Internal medicine medicine Humans Pathological Neoadjuvant therapy Aged Neoplasm Staging business.industry technology industry and agriculture Odds ratio Middle Aged Prognosis equipment and supplies medicine.disease Neoadjuvant Therapy Confidence interval Treatment Outcome Female Thiolester Hydrolases business hormones hormone substitutes and hormone antagonists Follow-Up Studies |
| Zdroj: | The Cancer Journal. 19:10-17 |
| ISSN: | 1528-9117 |
| Popis: | PURPOSE USP-11, a member of the ubiquitin-specific protease family, has emerged as an essential regulator of double-strand break repair. Few studies have shown that silencing USP-11 led to hypersensitivity to poly(ADP-ribose) polymerase inhibition, ionizing radiation, and DNA-damaging agents. We sought to examine the predictive and prognostic relevance of USP-11 in patients treated with neoadjuvant systemic therapy (NST) for breast cancer. METHODS Fifty-six women who were treated with NST for breast cancer between 1999 and 2004 were included in the study. The Kaplan-Meier product-limit method was used to estimate disease-free survival and overall survival rates. Logistic regression models were fit to determine the associations between USP-11 status, pathological complete response (pCR), and survival. RESULTS Sixteen patients (29%) had high-USP-11-expressing tumors, and 40 (71%) patients had low-USP-11-expressing tumors. No significant differences were observed in pCR rates with respect to USP-11 status. At a median follow-up of 7.4 years, 33 patients (59%) experienced a disease recurrence or death. Patients with high-USP-11-expressing tumors had a higher risk of recurrence (odds ratio [OR], 3.87; 95% confidence interval [CI], 1.51-9.93; P = 0.005) and death (OR, 6.03; 95% CI, 2.00-18.17; P = 0.001) than those with low-USP-11-expressing tumors. Patients who did not achieve a pCR had an increased risk of recurrence (OR, 5.16; 95% CI, 1.16-23.07; P = 0.03). CONCLUSIONS Our data indicate that USP-11 is not a predictor of a pCR after anthracycline-taxane-containing NST for breast cancer. Low USP-11 expression was independently correlated with better survival outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|